XML 92 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
Segment
shares
Dec. 31, 2020
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]    
Number of operating segments | Segment 1  
Other-than-temporary fair value adjustments of available-for-sale securities, recognized in earnings $ 0 $ 0
Deferred offering costs 200,000 200,000
Off-balance sheet risks, assets 0 0
Off-balance sheet risks, liabilities 0 0
Impairment charges recorded on long-lived assets 0 0
Other comprehensive (loss) income $ (0) $ (43,000)
Convertible preferred stock issued | shares 0 0
Convertible preferred stock outstanding | shares 0 0
Construction In Progress    
Summary Of Significant Accounting Policies [Line Items]    
Depreciation expense $ 0  
Revenue Benchmark | Jazz Pharmaceuticals Ireland Limited | Revenue from Rights Concentration Risk    
Summary Of Significant Accounting Policies [Line Items]    
Concentration risk percentage 49.00% 22.00%
Revenue Benchmark | Sarepta Therapeutics | Revenue from Rights Concentration Risk    
Summary Of Significant Accounting Policies [Line Items]    
Concentration risk percentage 51.00% 78.00%
Maximum    
Summary Of Significant Accounting Policies [Line Items]    
FDIC insured amount $ 250,000 $ 250,000
Maximum | Term Loan    
Summary Of Significant Accounting Policies [Line Items]    
Deferred financing costs $ 100,000 $ 100,000